US 2020/0003792 A1 · DIAGNOSTIC METHOD

Abstract

The disclosure is directed to a method of diagnosing a prostate condition in a subject by determining, in a sample obtained from a subject, levels of a plurality of constituents selected from the group consisting of Ca, K, Mg, Zn, Ag, AI, Au, B, Ba, Bi, Br, Cd, Ce, Co, Cr, Cs, Cu, Dy, Er, Fe, Gd, Hg, Ho, La, Li, Mn, Na, Nd, Ni, P, Pb, Pr, Rb, S, Sb, Sc, Se, Si, Sm, Sr, Tb, Th, Tl, U, Y, and Zr. A combination of the levels of the plurality of constituents in the sample is compared with a combination of control levels of the same plurality of constituents. A difference between the combinations is indicative of the prostate condition.

Claims8

Dependent claims

A method of diagnosing a prostate condition in a subject, comprising:

determining, in a sample obtained from a subject, levels of a plurality of constituents selected from the group consisting of Ca, K, Mg, Zn, Ag, Al, Au, B, Ba, Bi, Br, Cd, Ce, Co, Cr, Cs, Cu, Dy, Er, Fe, Gd, Hg, Ho, La, Li, Mn, Na, Nd, Ni, P, Pb, Pr, Rb, S, Sb, Sc, Se, Si, Sm, Sr, Tb, Th, Tl, U, Y, and Zr;
and
comparing a combination of the levels of the plurality of constituents in the sample with a combination of control levels of the same plurality of constituents, in which a difference between the combinations is indicative of the prostate condition.

Dependencies are inferred from the claim text.

Facts

Application

16/502,543Filed 3 Jul 2019

Priority

GB 1408875.119 May 2014

Published

2 Jan 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

G01N 33/84
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing:…
G01N 33/57555
For cancer: of the prostate
G01N 2800/342
Genitourinary disorders: prostate diseases, e.g. BPH, prostatitis
G01N 2800/7028
Proliferation: cancer

Diagnostic method

Life of this patent

Diagnostic method

Life of this patent

Abstract

Claims8